If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
The below information is provided in response to your request and may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above.
Forteo® (teriparatide [rDNA origin] injection) is rapidly and extensively absorbed following subcutaneous injection, with a Cmax at approximately 30 minutes (Forteo Package Insert, 2012; Satterwhite, 2010).
The half-life of teriparatide in serum is approximately 1 hour when administered by subcutaneous injection (Forteo Package Insert, 2012; Satterwhite, 2010).
Systemic clearance of teriparatide is approximately 62 L/hr in women and 94 L/hr in men, which exceeds the rate of normal liver plasma flow, consistent with both hepatic and extra-hepatic clearance (Forteo Package Insert, 2012).
Teriparatide is rapidly eliminated with a decrease to non-quantifiable concentrations within 3 hours of the dose (Forteo Package Insert, 2012).
Enclosed Prescribing Information
The published references below are available upon request by contacting 1-800-LillyRx.
Date of Last Review: February 12, 2017